Monsanto Fined $2.5 Million For EPA Violations

Monsanto. has agreed to pay a $2.5 million penalty for misbranding biotech cotton seed products in what regulators called the largest civil administrative penalty settlement ever received for violating U.S. insecticide law.

The U.S. Environmental Protection Agency said St. Louis-based Monsanto, the world's largest seed company, violated the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA) when it sold and distributed cotton seed products containing genetically engineered pesticides in a manner that violated restrictions Monsanto had told the EPA it would adhere to.

"This agreement shows that when a company violates the law by distributing misbranded pesticides, EPA will take action," said Cynthia Giles, assistant administrator for EPA's Office of Enforcement and Compliance Assurance in a statement.

The EPA said it found that between 2002 and 2007, Monsanto distributed or sold Bollgard and Bollgard II cotton seed products contain genetically engineered pesticides more than 1,700 times nationwide without the planting restrictions that EPA required to protect against pest resistance.

"People who manufacture and distribute pesticide products must follow the federal registration requirements," said Steve Owens, assistant administrator for EPA's Office of Chemical Safety and Pollution Prevention. "These requirements are critical to preventing the development and spread of insect resistance." EPA officials said Monsanto has since corrected the misbranding problems.

Monsanto officials were not immediately available for comment.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
08.08.2025 • News

Carbios und Indorama kooperieren bei rPET

Carbios wird recycelte Monomere bereitstellen, die von Indorama Ventures zu Filamenten für die Verstärkung von Reifen des Herstellers Michelin verarbeitet werden.

Photo
19.05.2025 • NewsChemie

OQ Chemicals firmiert künftig wieder als Oxea

Der bis Mai 2020 unter dem Namen Oxea bekannte Hersteller von Oxo-Zwischenprodukten und Oxo-Derivaten, der zwischenzeitlich zum Omanischen Energieunternehmen OQ gehörte und unter dem Namen OQ Chemicals firmierte, kehrt zu seinem alten Namen und seinen Wurzeln zurück.